Two key proteins linked to cell division can reliably predict disease recurrence in prostate cancer after radiotherapy treatment, according to new research.

A shorter course of radiotherapy, administered through fewer, higher intensity doses, is as well tolerated over five years as longer treatment courses for treating prostate cancer, long-term results of a clinical trial show.

A major clinical trial has shown that changing the way radiotherapy is delivered could significantly reduce the side effects associated with radiotherapy treatment for prostate cancer.